Advisory boards
Our advisory boards tap the expertise of world-class leaders in medicine, genetics, and public policy. Their input helps to guide Navigenics as the company pioneers the new field of personalized genomic medicine.
Clinical advisory board
- Chair: David Agus, M.D. (Navigenics Co-founder)
David Agus is a prostate cancer specialist and Professor of Medicine at the University of Southern California. He is the Director of the USC Center for Applied Molecular Medicine and the USC Westside Prostate Cancer Center. In addition to co-founding Navigenics, Dr. Agus also founded Oncology.com, the largest cancer internet resource/community. More
- Carlos Camargo, M.D.
Carlos Camargo is an emeritus clinical professor of medicine at Stanford University Medical Center, where he has been on the faculty for more than 40 years. He is the director of the medical history course and a three-time recipient of the Kaiser Award for Excellence in Teaching. More
- Daniel Federman, M.D.
Daniel Federman is senior dean for alumni relations and clinical teaching at Harvard Medical School, where he has been on the faculty for more than 40 years. An endocrinologist by training, Dr. Federman maintains an active clinical practice in Boston. More
- Bruce E. Landon, M.D.
Bruce E. Landon is associate professor of health care, Harvard Medical School, and associate professor of medicine, Beth Israel Deaconess Medical Center. His research interests include assessing the impact of different characteristics of physician and health care organizations on the provision of health care. More
Scientific advisory board
- David Botstein, Ph.D.
David Botstein and colleagues proposed a method in 1980 for mapping genes that laid the groundwork for the Human Genome Project. He is director of the Lewis-Sigler Institute for Integrative Genomics and Anthony B. Evnin professor of genomics at Princeton University and a member of the National Academy of Sciences. More
- Isaac Kohane, M.D., Ph.D.
Isaac Kohane is an associate professor at Harvard Medical School, where he uses genomics and computer science to study cancer and the development of the brain, with emphasis on autism. He has developed computer systems to allow hospitals to be used as "living laboratories" to study the genetic basis of disease while preserving patient privacy. More
- Dietrich Stephan, Ph.D., Co-founder and Chief Science Officer
Dietrich Stephan is a human geneticist on the faculty of the Translational Genomics Research Institute and chairman of the National Institutes of Health Neuroscience Microarray Consortium. He has identified genes that predispose to disorders such as autism, exercise-induced heart attacks and sudden infant death syndrome, and contributed to understanding a multitude of common disorders such as Alzheimer's disease. More
- Spencer Wells, Ph.D.
Spencer Wells is a leading population geneticist, the director of the Genographic Project and a National Geographic Explorer-in-Residence. A scientist, author and documentary filmmaker, he has dedicated much of his career to studying humankind's family tree and closing the gaps in our knowledge of human migration. More
Policy and ethics task force
- Chair: Greg Simon
Greg Simon is president of FasterCures/The Center for Accelerating Medical Solutions. FasterCures aims to discover and promote ways to accelerate new medical treatments. Previously, Mr. Simon was the chief domestic policy advisor to Vice President Al Gore from 1993 to 1997. More
- Amy DuRoss
Amy DuRoss serves as Vice President, Policy and Business Affairs, for Navigenics. A longtime patient advocate, Amy’s work has focused on federal and state funding projects ranging from the Federal Special Diabetes Program in 2002, the first stand-alone unanimous consent healthcare resolution in the history of the U.S. to the $3 Billion California Stem Cell Research and Cures initiative, passed in 2004. More
- Paul Slovic, Ph.D.
Paul Slovic a founder and president of Decision Research, studies human judgment, decision-making and risk analysis. He and his colleagues have developed methods to describe risk perceptions and measure their impacts on individuals, industry and society. More
